The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Immunomodulating Therapy With Intravenous Immunoglobulin in Patients With Chronic Heart Failure
Abstract
Background —Congestive heart failure (CHF) is characterized by enhanced immune activation, and immune-mediated mechanisms may play a pathogenic role in this disorder. Based on the immunomodulatory effects of intravenous immunoglobulin (IVIG), we hypothesized that IVIG could downregulate inflammatory responses in CHF patients and have potential beneficial effects on the left ventricular ejection fraction (LVEF). Methods and Results —Forty patients with chronic symptomatic CHF and LVEF of <40%, stratified according to cause (ie, ischemic and idiopathic dilated cardiomyopathy), were randomized in a double-blind fashion to receive therapy with IVIG or placebo for a total period of 26 weeks. Our main findings were that (1) IVIG, but not placebo, induced a marked rise in plasma levels of the anti-inflammatory mediators interleukin (IL)-10, IL-1 receptor antagonist, and soluble tumor necrosis factor receptors; (2) significantly correlated with these anti-inflammatory effects, IVIG, but not placebo, induced a significant increase in LVEF from 26±2% to 31±3% ( P <0.01), and this was found independent of the cause of heart failure; and (3) N-terminal pro–atrial natriuretic peptide decreased significantly after induction therapy and continued to decrease toward the end of study during IVIG therapy ( P <0.001) but remained unchanged during placebo. Conclusions —We demonstrated an IVIG-induced change in the balance between inflammatory and anti-inflammatory cytokines that favored an anti-inflammatory net effect in CHF. This effect was significantly correlated with an improvement in LVEF, suggesting a potential for immunomodulating therapy in addition to optimal conventional cardiovascular treatment regimens in CHF patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Negative Inotropic Effects of Cytokines on the Heart Mediated by Nitric Oxide
Finkel, M. S., Oddis, C. V., Jacob, T. D., Watkins, S. C., Hattler, B. G., & Simmons, R. L. (1992) · Science · doi:10.1126/science.1631560 · Cited by 1,628
Inhibition of Toxic Epidermal Necrolysis by Blockade of CD95 with Human Intravenous Immunoglobulin
Viard, I., Wehrli, P., Bullani, R., Schneider, P., Holler, N., Salomon, D., Hunziker, T., Saurat, J.-H., Tschopp, J., & French, L. E. (1998) · Science · doi:10.1126/science.282.5388.490 · Cited by 1,005
Tumor Necrosis Factor-α and Tumor Necrosis Factor Receptors in the Failing Human Heart
Torre-Amione, G., Kapadia, S., Lee, J., Durand, J.-B., Bies, R. D., Young, J. B., & Mann, D. L. (1996) · Circulation · doi:10.1161/01.cir.93.4.704 · Cited by 989
Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin
(1999) · Transfusion Medicine Reviews · doi:10.1016/s0887-7963(99)80071-6 · Cited by 869
Protective Role of Interleukin-10 in Atherosclerosis
Mallat, Z., Besnard, S., Duriez, M., Deleuze, V., Emmanuel, F., Bureau, M. F., Soubrier, F., Esposito, B., Duez, H., Fievet, C., et al. (1999) · Circulation Research · doi:10.1161/01.res.85.8.e17 · Cited by 831
Bozkurt, B., Kribbs, S. B., Clubb, F. J., Michael, L. H., Didenko, V. V., Hornsby, P. J., Seta, Y., Oral, H., Spinale, F. G., & Mann, D. L. (1998) · Circulation · doi:10.1161/01.cir.97.14.1382 · Cited by 821
Krown, K. A., Page, M. T., Nguyen, C., Zechner, D., Gutierrez, V, Comstock, K. L., Glembotski, C. C., Quintana, P. J., & Sabbadini, R. A. (1996) · Journal of Clinical Investigation · doi:10.1172/jci119114 · Cited by 728
Yokoyama, T., Vaca, L., Rossen, R. D., Durante, W., Hazarika, P., & Mann, D. L. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116834 · Cited by 717
Manipulating the Immune System with Immune Globulin
Oates, J. A., Wood, A. J. J., & Dwyer, J. M. (1992) · New England Journal of Medicine · doi:10.1056/nejm199201093260206 · Cited by 648
Libby, P., Egan, D., & Skarlatos, S. (1997) · Circulation · doi:10.1161/01.cir.96.11.4095 · Cited by 556
Cited by
Caforio, A. L. P., Pankuweit, S., Arbustini, E., Basso, C., Gimeno-Blanes, J., Felix, S. B., Fu, M., Heliö, T., Heymans, S., Jahns, R., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht210 · Cited by 3,479
Viral myocarditis—diagnosis, treatment options, and current controversies
Pollack, A., Kontorovich, A. R., Fuster, V., & Dec, G. W. (2015) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2015.108 · Cited by 657
Inflammatory mediators in chronic heart failure: an overview
Anker, S. D., & von Haehling, S. (2004) · Heart · doi:10.1136/hrt.2002.007005 · Cited by 627
Malkin, C. J., Pugh, P. J., West, J. N., van Beek, E. J. R., Jones, T. H., & Channer, K. S. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehi443 · Cited by 413
Inflammation and chronic heart failure–potential therapeutic role of intravenous immunoglobulin
Aukrust, P., Yndestad, A., Damås, J. K., & Gullestad, L. (2004) · Autoimmunity Reviews · doi:10.1016/s1568-9972(03)00103-4 · Cited by 37
Self-citation
Metadata
- Authors
- Gullestad, L., Aass, H., Fjeld, J. G., Wikeby, L., Andreassen, A. K., Ihlen, H., Simonsen, S., Kjekshus, J., Nitter-Hauge, S., Ueland, T., Lien, E., Frøland, S. S., & Aukrust, P.
- Venue
- Circulation
- Published
- 2001-01-16
- Volume
- 103
- Issue
- 2
- Pages
- 220-225
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W1966836886
- Cited by
- 349
- References
- 26
- FWCI
- 17.91
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Immunomodulating Therapy With Intravenous Immunoglobulin in Patients With Chronic Heart Failure. https://app.cochat.ai/papers/10.1161/01.cir.103.2.220
- The paper
- Gullestad, L., Aass, H., Fjeld, J. G., Wikeby, L., Andreassen, A. K., Ihlen, H., Simonsen, S., Kjekshus, J., Nitter-Hauge, S., Ueland, T., Lien, E., Frøland, S. S., & Aukrust, P. (2001). Immunomodulating Therapy With Intravenous Immunoglobulin in Patients With Chronic Heart Failure. Circulation. https://doi.org/10.1161/01.cir.103.2.220
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
